골육종 : 신규 요법, 미충족 수요 및 TPP 인사이트 보고서(2026년)

Osteosarcoma Emerging Therapy and TPP Insights

Thelansis's "Osteosarcoma Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Osteosarcoma Overview

Osteosarcoma is a highly aggressive primary malignant bone tumor characterized by the production of osteoid by malignant mesenchymal cells. It predominantly affects adolescents and young adults, typically arising in the metaphyseal regions of long bones such as the distal femur and proximal tibia.

Patients commonly present with localized bone pain and swelling, often worsening at night. The disease has a strong propensity for early metastasis, particularly to the lungs, which significantly impacts prognosis.

The standard of care involves a multimodal approach, including:

• Neoadjuvant multi-agent chemotherapy
• Surgical resection (often limb-salvage procedures)
• Adjuvant chemotherapy

Outcomes are heavily dependent on histological response to chemotherapy and metastatic status at diagnosis. Despite aggressive treatment, survival rates for metastatic or relapsed disease remain poor, highlighting significant unmet need.

Key Highlights

• In the United States, incident cases are projected to increase from 2.0K in 2025 to 2.2K by 2035, reflecting a low growth rate (1-1.5% CAGR).
• Disease burden is driven by: High rates of metastasis at diagnosis & Limited treatment options in relapsed/refractory settings

Market Overview

• The osteosarcoma market in Germany is projected to grow from $27M in 2025 to $45M by 2035, reflecting a CAGR of 5%, driven by incremental innovation and improved treatment access.
• Incidence growth remains low (1-1.5% CAGR), indicating: Stable disease burden & Market expansion driven by treatment innovation rather than patient volume

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country.

Companies Mentioned

• Hansoh BioMedical R&D Company
• MedPacto, Inc.
• Emerald Clinical Inc.
• Tcelltech Inc.
• Circle Pharma
• Cellectar Biosciences, Inc.
• Jazz Pharmaceuticals
• Inhibrx Biosciences, Inc
• Valo Therapeutics Oy
• Amgen
• Eli Lilly and Company
• Shanghai Pharmaceuticals Holding Co., Ltd
• GlaxoSmithKline
• Hangzhou DAC Biotechnology Co., Ltd.
• Iovance Biotherapeutics, Inc.
• USWM CT, LLC
• UNICANCER
• Valent Technologies, LLC
• SEED Therapeutics, Inc.
• Actuate Therapeutics Inc.
• Pfizer
• Merck Sharp & Dohme LLC
• Endeavor Biomedicines, Inc.
• Hoffmann-La Roche

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)